Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.9052W HIGH $10.54
Volume
1.16 K
Value Traded
7.08 K
Short % Float
0.21%
+0.94%Week
-6.96%1 Month
+5.11%3 Month
+113.15%6 Month
-100%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
7.82 M
EPS (TTM)
-11.43
P/E Ratio
-
Ent. Value
-12.17 M
Total Shares
1.46 M
Float Shares
1.44 M
Insiders
1.44%
Institutions
19.19%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CNSP Catalyst Timeline
Dated clinical, regulatory and corporate events for CNS Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for CNS Pharmaceuticals, Inc.
161Total events
4Upcoming
28Tier-1 (high impact)
2019 to 2026Coverage
Upcoming catalysts 2
Event history 50
●Trial CompletionBerubicinFiledTrial
Global clinical trial of Berubicin for glioblastoma is complete
glioblastomasource ↗
▼Topline ReadoutBerubicinFiledClinical Data
Reported Primary Analysis of Berubicin Monotherapy in 2nd line GBM
Glioblastoma Multiforme (GBM)source ↗
▼Topline ReadoutBerubicinFiledClinical Data
Reported Primary Analysis of Berubicin Monotherapy in 2nd line GBM
Glioblastoma Multiforme (GBM)source ↗
◆Timing GuidancePresentation
Plan to engage with regulators to design potential registration study in 2025
Glioblastoma Multiforme (GBM)source ↗
◆FDA Feedback ReceivedFDA Meeting
Plan to engage with regulators to design potential registration study in 2025
Glioblastoma Multiforme (GBM)source ↗
▲EU Orphan DesignationBerubicinFiledEx-US Regulatory
Upcoming filing in EU for Orphan Drug Designation
Glioblastoma Multiforme (GBM)source ↗
◆Trial InitiationTrial
Plan to engage with regulators to design potential registration study for TPI 287
Glioblastoma Multiforme (GBM)source ↗
◆Topline ReadoutBerubicinFiledClinical Data
Topline data expected from Berubicin GBM study
glioblastoma multiforme (GBM)source ↗
▲Enrollment CompleteBerubicinFiledTrial
Berubicin pivotal trial fully enrolled with 252 subjects
Glioblastoma Multiforme (GBM)source ↗
▼Equity OfferingCorporate
Pricing of $3 million registered direct offering of common stock at $0.17 per share
▲Partnership / LicenseCorporate
Exclusive license agreement with Cortice Biosciences for TPI 287
glioblastoma multiforme (GBM)source ↗
▼Equity OfferingCorporate
Pricing of registered direct offering and concurrent private placement
▼Equity OfferingCorporate
Pricing of registered direct offering and concurrent private placement
▼Equity OfferingCorporate
Pricing of registered direct offering and concurrent private placement
▲Enrollment CompleteBerubicinFiledTrial
Full enrollment achieved in Berubicin GBM study
glioblastoma multiforme (GBM)source ↗
▲Enrollment CompleteBerubicinFiledTrial
Enrollment completed in potentially pivotal GBM study evaluating Berubicin
glioblastoma multiforme (GBM)source ↗
▲Enrollment CompleteBerubicinFiledTrial
Completion of Planned Enrollment in Potentially Pivotal Berubicin Trial
Glioblastoma Multiforme (GBM)source ↗
▲Interim AnalysisBerubicinFiledTrial
DSMB recommends continuing Berubicin trial without modification after interim analysis
glioblastoma multiforme (GBM)source ↗
▲DSMB ReviewBerubicinFiledTrial
DSMB recommends continuation without modification after interim futility analysis
glioblastoma multiforme (GBM)source ↗
▲DSMB ReviewBerubicinFiledTrial
Successful Interim Analysis/Data - DSMB recommended to continue trial without modification
Glioblastoma Multiforme (GBM)source ↗
▲Enrollment CompleteBerubicinFiledTrial
Expected full enrollment in December 2023
recurrent glioblastoma multiforme (GBM)source ↗
◆Interim AnalysisBerubicinFiledTrial
Topline results of interim analysis expected in December 2023
recurrent glioblastoma multiforme (GBM)source ↗
▲Enrollment UpdateBerubicinFiledTrial
Enrollment reached 239 patients
recurrent glioblastoma multiforme (GBM)source ↗
▲Interim AnalysisBerubicinFiledTrial
Successful Interim Analysis/Data
Glioblastoma Multiforme (GBM)source ↗
◆Enrollment CompleteBerubicinFiledTrial
Complete enrollment expected in Q4 2023
glioblastoma (GBM)source ↗
▼Equity OfferingCorporate
Raised $2.6 million in warrant inducement and ATM placements in October 2023
●Enrollment MilestoneBerubicinFiledTrial
Enrollment of 229th Patient
Glioblastoma Multiforme (GBM)source ↗
▲Enrollment MilestoneBerubicinFiledTrial
Enrollment of 229th Patient
Glioblastoma Multiforme (GBM)source ↗
▲Enrollment MilestoneBerubicinFiledTrial
Enrolled 180 patients in Berubicin trial
glioblastoma (GBM)source ↗
◆Enrollment MilestoneBerubicinFiledTrial
Enrollment of 200th patient expected in Q3 2023
glioblastoma (GBM)source ↗
◆Interim AnalysisBerubicinFiledTrial
Interim analysis results expected
glioblastoma multiforme (GBM)source ↗
▲Enrollment MilestoneBerubicinFiledTrial
Enrolled over 100 patients in potentially pivotal trial
glioblastoma multiforme (GBM)source ↗
▲Other Regulator MilestoneBerubicinFiledEx-US Regulatory
Received approval from Competent Authority and Central Ethics Committee in Italy for GBM study
glioblastoma multiforme (GBM)source ↗
▲First Patient DosedBerubicinFiledTrial
Enrolled first patients in Switzerland and Spain
glioblastoma multiforme (GBM)source ↗
Past FDA Catalysts and PDUFA Decisions
How CNSP actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-06-30 | Berubicin | Phase 2 topline data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D28 / 100
Pipeline Score
$1M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.2x
rNPV / MCap
Top 74%
Micro Cap(rank 489 of 660)
Percentile Rank
CNS Pharmaceuticals, Inc. faces pipeline headwinds (28/100), with $91M risk-adjusted pipeline value, led by Berubicin in Glioblastoma Multiforme, Adult (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Berubicin Small moleculeNCT04762069 | Glioblastoma Multiforme, Adult | Phase 2 | ACTIVE NOT_RECRUITING | 252 | Jul 15, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every CNSP program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Berubicin Fast TrackOrphan | Glioblastoma Multiforme | 2025-07-15 | Did not a statistically significant difference in overall survivalRead More | NASDAQ: CNSP July 2025 2 Forward Looking Statements This presentation incorporates information from materials filed with the SEC and contains forward - looking statements. All statements contained herein other than stateRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Levin RamiOfficer (CEO and President) | Option | -4,750 14,250 held | $0.00 | 08/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CNSP
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0 % | 109.00 K | 45.83 K |
CNSP Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CNSP ranks across every disease it competes in
Competitive Position is a premium feature
See how CNSP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCNSP News
CNSPCNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth
CNS Pharmaceuticals has outlined its business development strategy in a recent virtual investor segment. Chief Business Officer Dylan Wenke discussed the company's focus on oncology and neurology, emphasizing a rigorous evaluation process for potential opportunities. The company aims to build a differentiated portfolio of assets that address significant unmet medical needs while creating long-term value for shareholders.
Read more →CNSPCNS Pharmaceuticals Participates in the Virtual Investor “Why Now” On-Demand Conference
CNS Pharmaceuticals participated in the Virtual Investor 'Why Now' on-demand conference, where CEO Rami Levin discussed the company's strategic transformation and financial enhancements following a recent financing round. The company aims to build a portfolio of innovative therapies addressing significant unmet medical needs while focusing on long-term growth and shareholder value.
Read more →CNSP▼ -8.9%on this news
CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation
CNS Pharmaceuticals reported strong second quarter results for 2026, highlighting a cash position of approximately $20 million following an oversubscribed financing round of $22.5 million. The company is executing a strategic transformation to diversify its pipeline beyond glioblastoma. Despite a net loss of $2.6 million, management remains optimistic about future growth and value creation.
Read more →CNSPCNS Pharmaceuticals CFO, Steve O’Loughlin, Highlights Company’s Recent $22.5M Financing in Virtual Investor “What This Means” Segment
CNS Pharmaceuticals recently completed an oversubscribed $22.5 million financing, as discussed by CFO Steve O’Loughlin in a Virtual Investor segment. The financing reflects investor confidence in the company's strategic transformation and acquisition-focused approach. O’Loughlin emphasized the importance of institutional support for advancing the company's growth and creating long-term shareholder value.
Read more →CNSP▲ +6.7%on this news
CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company’s Recent Strategic Transformation Progress
CNS Pharmaceuticals participated in a Virtual Investor CEO Connect segment where CEO Rami Levin discussed the company's recent $22.5 million financing and its strategic pivot. He outlined the progress made and the company's plans for pipeline development aimed at enhancing shareholder value. Levin emphasized key milestones for investors to monitor moving forward.
Read more →CNSP▼ -9.2%on this news
CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress
CNS Pharmaceuticals reported its first quarter 2026 financial results, highlighting a strategic transformation led by a new executive team. The company secured $22.5 million in financing to pursue acquisition opportunities for clinical-stage assets. Despite a net loss of approximately $4.9 million, the company aims to advance its pipeline and create long-term shareholder value.
Read more →CNSP▼ -9.8%on this news· ran to -23% by day 3shared move
CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research
Oncotelic Therapeutics is progressing in the development of its intranasal nose-to-brain (N2B) delivery system aimed at improving CNS drug delivery, particularly for Alzheimer's disease and biodefense applications. The company has announced a strategic agreement with Lunai Bioworks to monetize its N2B delivery system for specific applications. Despite the innovative solutions being explored, challenges persist with the blood-brain barrier, resulting in a high failure rate for therapeutic candidates. The ongoing demand for effective CNS interventions underscores the importance of Oncotelic's technology in both civilian and biodefense contexts.
Read more →CNSP▼ -7.3%on this news· ran to -31% by day 3shared move
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
Oncotelic Therapeutics is making strides in central nervous system (CNS) drug delivery by advancing technologies designed to bypass the blood-brain barrier (BBB). Their proprietary nose-to-brain (N2B) delivery system has garnered attention, particularly in the context of rising Alzheimer’s disease cases and biodefense needs. Recently, Oncotelic announced a strategic monetization with Lunai Bioworks concerning its N2B system, highlighting the growing demand for effective CNS drug delivery solutions. The emphasis on overcoming delivery challenges is seen as key to improving therapeutic outcomes for neurodegenerative diseases.
Read more →CNSP▲ +239.2%on this news
CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing
CNS Pharmaceuticals has announced a successful private placement financing, raising approximately $22.5 million from notable healthcare investors. The funds will be utilized to acquire clinical-stage assets aligned with the company's new corporate strategy. CNS aims to enhance its pipeline and create near-term value for patients and shareholders.
Read more →CNSP▼ -11.6%on this news· ran to -27% by day 3
CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline
CNS Pharmaceuticals has launched a new corporate strategy to develop a high-value pipeline in neurology and oncology. The newly formed executive team will focus on acquiring differentiated therapeutic assets, moving away from a singular focus on glioblastoma. The company plans to out-license legacy assets while prioritizing programs with strong clinical potential and unmet medical needs.
Read more →CNSP▼ -11.6%on this news· ran to -27% by day 3shared move
cnspharma.com NASDAQ: CNSP March 2026 Investor Presentation 2 Forward Looking Statements This presentation incorporates information from materials filed with the SEC and contains forward - looking statements . All statem
CNS Pharmaceuticals has announced a strategic pivot under a new executive team aimed at repositioning the company for long-term success in neurology and oncology. The new strategy emphasizes disciplined capital allocation and a focus on high-value, unmet medical needs. A comprehensive review has led to the targeting of preclinical and clinical-stage programs that show significant commercial viability. Additional highlights include the potential out-licensing of legacy programs to unlock value for shareholders.
Read more →CNSPCNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team
CNS Pharmaceuticals has appointed Dr. Lynne Kelley as Chief Medical Officer, completing its executive leadership team. Dr. Kelley brings extensive experience in oncology and rare diseases, having successfully led numerous clinical programs and regulatory approvals globally. Her expertise is expected to drive the company's strategic growth and enhance its drug development pipeline.
Read more →CNSP▼ -5.8%on this news
CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company’s Recently Initiated Strategic Transformation
CNS Pharmaceuticals has appointed key executives to its leadership team to support its strategic transformation. The new appointments include Steven O'Loughlin as CFO, Eric Faulkner as CTO, and Dylan Wenke as CBO, all effective March 2, 2026. The company aims to enhance operational execution and drive value creation through disciplined growth and a focus on pipeline optimization.
Read more →CNSPCNS Pharmaceuticals Issues Letter to Shareholders - January 27, 2026
CNS Pharmaceuticals has issued a letter to shareholders from its new CEO, Rami Levin, outlining a strategic focus on pipeline optimization and value creation. Levin emphasizes the importance of addressing unmet medical needs and refining the development of their lead asset, TPI 287. The company aims to enhance its operational structure and ensure disciplined capital allocation to maximize shareholder returns.
Read more →CNSPCNS Pharmaceuticals Issues Letter to Shareholders
CNS Pharmaceuticals has issued a letter to shareholders from its new CEO, Rami Levin, outlining a strategic focus on pipeline optimization and value creation. Levin emphasizes a patient-first approach and the importance of refining their lead asset, TPI 287, to enhance its clinical potential. The company aims to strengthen its operational execution and maintain transparent communication with shareholders.
Read more →CNSP▼ -6.4%on this news
CNS Pharmaceuticals Announces CEO Transition
CNS Pharmaceuticals has announced the appointment of Rami Levin as the new CEO, succeeding John Climaco. Levin, an industry veteran with nearly 30 years of experience, is expected to lead the company through its next growth phase, focusing on the development of TPI 287, a promising anti-cancer drug. The transition aims to enhance the company's strategic direction and operational capabilities.
Read more →CNSPCNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
CNS Pharmaceuticals reported its third quarter 2025 financial results, highlighting progress with its lead candidate TPI 287 for glioblastoma treatment. The company has sufficient cash to fund operations into mid-2026 and is preparing for a Phase 2 trial. Early data suggests TPI 287 may effectively cross the blood-brain barrier, enhancing treatment options for patients.
Read more →CNSPCNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting
CNS Pharmaceuticals has announced that three of its abstracts have been accepted for poster presentations at the Society of NeuroOncology's 30th Annual Meeting. The presentations will cover the activity of Berubicin against pediatric diffuse midline glioma, the evaluation of TPI 287 in a Phase 2 trial for glioblastoma, and results from a clinical trial comparing Berubicin and Lomustine in glioblastoma patients. The event will take place in Honolulu, HI from November 19-23, 2025.
Read more →CNSPCNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
CNS Pharmaceuticals, Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York. The company will also hold one-on-one meetings with investors. Their drug candidate, TPI 287, has shown potential in treating CNS tumors and has been well-tolerated in clinical trials.
Read more →About CNS Pharmaceuticals, Inc.
Headquarters2100 WEST LOOP SOUTH, HOUSTON, TX, 77027
BIOPHARMAWATCH ELITE PLUS
Trade the next CNSP catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime